PresentationLinda Nyberg Good afternoon, and a big welcome to all of you here in Wallenbergsalen, and also a big welcome to you who are watching online. And as you know, this is Sdiptech's Capital Markets Day 2025. I'm Linda Nyberg, and I will be your host today. So I'm really looking forward to this because last time I was hosting a Capital Markets Day for Sdiptech, was 2021. And for those of you who remember, that was during the pandemic. So I do not have the pleasure to meet all of you in-person. So I th ...

Core Insights - The company announced a three-year business strategy aiming for up to 10% revenue growth by 2026 [1] - The seasonal vaccine franchise is expected to expand from three to up to six approved products by 2028 [1] - The company targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene [1] - Expected GAAP operating expenses for 2026 and 2027 are improved by approximately $0.5 billion each year, with a path to targeted cash breakeven in 2028 [1]

Overview - Lean Six Sigma is a business strategy focused on efficiency [1] - The strategy achieves efficiency by identifying waste and redundancy [1] Methodology - Lean Six Sigma develops solutions to address the identified causes of waste [1]